文献速递免疫规划职业卫生

评估美国从事高致病性禽流感病毒工作的实验室人员对甲型H5N1流感疫苗的接种意愿

Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States.
PubMed 文献 · Vaccine · 2017-12-02

研究通过匿名网络调查美国42家注册实体的BSL-3E实验室人员,评估其对甲型H5N1疫苗的需求。共收到131份回复,估计回复率为15%,49%的受访者有兴趣接种疫苗。学生(80%)和超过50%时间在BSL-3E区域工作的人员(64%)兴趣最高;61%的不感兴趣者认为疫苗不会提供额外保护。

要点

  • 49%的受访实验室人员有兴趣接种甲型H5N1疫苗。
  • 学生兴趣最高(80%),其次为超过50%时间在BSL-3E区域工作者(64%)。
  • 61%的不感兴趣者认为疫苗不会提供额外保护。

核心结论

  • 半数回复的实验室工作人员有兴趣接种甲型H5N1流感疫苗。
  • 对职业暴露风险的实验室人员进行HPAI疫苗接种可与现有安全措施一起用于保护该人群。

研究设计与样本

  • 研究为匿名网络调查(EpiInfo 7.0),调查对象为2016年在美国农业部农业选择剂计划注册的42家实体中具有BSL-3E实验室访问权限的人员。
  • 共收到131份回复,包括33名主要研究者、26名研究科学家、24名技术员、15名博士后、6名学生和27名其他人员。
  • 回复的实验室人员中估计回复率为15%。

主要发现

  • 100名受访者报告在发生HPAI实验的BSL-3E区域工作,平均每周工作5.1-11.7小时。
  • 总体而言,49%的受访者有兴趣接种甲型H5N1疫苗。
  • 按角色划分,学生兴趣最高(80%),超过50%时间在BSL-3E区域工作的人员兴趣为64%。
  • 61%表示可能不感兴趣或不感兴趣的人认为疫苗不会对当前安全实践提供额外保护。

临床怎么用

  • 对职业暴露风险的实验室工作人员进行HPAI疫苗接种可与现有安全实践一起用于保护该人群。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Highly pathogenic avian influenza A (HPAI) viruses found in poultry and wild birds occasionally infect humans and can cause serious disease. In 2014, the Advisory Committee on Immunization Practices (ACIP) reviewed data from one licensed ASO3-adjuvanted influenza A(H5N1) vaccine for consideration of use during inter-pandemic periods among persons with occupational exposure. To guide vaccine policy decisions, we conducted a survey of laboratory workers to assess demand for HPAI vaccination. METHODS: We designed an anonymous web survey (EpiInfo 7.0) to collect information on demographics, type of work and time spent with HPAI viruses, and interest in HPAI vaccination. Eligible participants were identified from 42 entities registered with United States Department of Agriculture's Agricultural Select Agent program in 2016 and emailed electronic surveys. Personnel with Biosafety Level 3 enhanced (BSL-3E) laboratory access were surveyed. Descriptive analysis was performed. RESULTS: Overall, 131 responses were received from 33 principal investigators, 26 research scientists, 24 technicians, 15 postdoctoral fellows, 6 students, and 27 others. The estimated response rate was 15% among the laboratory personnel of responding principal investigators. One hundred respondents reported working in a BSL-3E area where HPAI experiments occurred with a mean time of 5.1-11.7 h per week. Overall, 49% were interested in receiving an A(H5N1) vaccine. By role, interest was highest among students (80%) and among those who spent >50% of their time in a BSL-3E area (64%). Most (61%) of those who said they might be or were not interested in vaccine believed it would not provide additional protection to current safety practices. CONCLUSIONS: Half of responding laboratory workers was interested in receiving an influenza A(H5N1) vaccine. HPAI vaccination of laboratory workers at risk of occupational exposure could be used along with existing safety practices to protect this population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Russell KE, Bresee JS, Katz JM, et al. Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States. Vaccine. 2017. PMID: 29199043. doi:10.1016/j.vaccine.2017.10.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。